ArticleBMC family practice2007
The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden.
Article in BMC family practice, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Cost-effectiveness of atrial fibrillation screening programmes across European nations.European heart journal. Quality of care & clinical outcomes · 2026Article
- Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study.Arquivos brasileiros de cardiologia · 2020Article
- Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings.BMC health services research · 2018Article
- Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.Thrombosis journal · 2015Article
- Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.BMJ open · 2014Article
- Atrial fibrillation: the cost of illness in Sweden.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.Journal of atrial fibrillationReview
- The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation.Journal of atrial fibrillationArticle
- Cost-Effectiveness of Dabigatran Exilate in Treatment of Atrial Fibrillation.Journal of atrial fibrillationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWarfarin is used for the prevention of stroke in chronic atrial fibrillation. The product has a narrow therapeutic index and to obtain treatment success, patients must be maintained within a given therapeutic range (International Normalised Ratio;INR). To ensure a wise allocation of health care resources, scrutiny of costs associated with various treatments is justified. The objective of this study was to estimate the health care cost of INR controls in patients on warfarin treatment with chronic atrial fibrillation in primary care in Sweden.
methodsData from various sources were applied in the analysis. Resource consumption was derived from two observational studies based on electronic patient records and two Delphi-panel studies performed in two and three rounds, respectively. Unit costs were taken from official databases and primary health care centres.
resultsThe mean cost of one INR control was SEK 550. The mean costs of INR controls during the first three months, the first year and during the second year of treatment were SEK 6,811, SEK 16,244 and SEK 8,904 respectively.
conclusionINR controls of patients on warfarin treatment in primary care in Sweden represent a substantial cost to the health care provider and they are particularly costly when undertaken in home care. The cost may however be off-set by the reduced incidence of stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.